公开(公告)号：US20240199594A1

公开(公告)日：2024-06-20

申请号：US18365392

申请日：2023-08-04

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle BRAUN ,  Emily HANAN ,  Steven T. Staben ,  Robert Andrew HEALD ,  Calum MACLEOD ,  Richard ELLIOTT

IPC: C07D413/14 ,  A61K31/553 ,  C07D267/08 ,  C07D498/04

CPC classification number: C07D413/14 ,  A61K31/553 ,  C07D267/08 ,  C07D498/04

Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:




or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

公开(公告)号：US20230025834A1

公开(公告)日：2023-01-26

申请号：US17447361

申请日：2021-09-10

Applicant: Genentech, Inc.

Inventor： Guosheng WU ,  Emily J. HANAN ,  Marie-Gabrielle BRAUN ,  Sharada S. LABADIE ,  Keira GARLAND ,  Richard M. PASTOR ,  Paul Anthony GIBBONS ,  Yuhong FU ,  Yun-Xing CHENG

IPC: C07K7/56

Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

公开(公告)号：US20240398781A1

公开(公告)日：2024-12-05

申请号：US18670608

申请日：2024-05-21

Applicant: GENENTECH, INC. ,  CONVELO THERAPEUTICS, INC.

Inventor： Marie-Gabrielle BRAUN ,  Georgette CASTANEDO ,  William VERNIER ,  Matthew VOLGRAF ,  James Guy BREITENBUCHER ,  Brad LANG

IPC: A61K31/4545 ,  A61K31/407 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  C07D495/10

Abstract: The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

公开(公告)号：US20240400579A1

公开(公告)日：2024-12-05

申请号：US18670520

申请日：2024-05-21

Applicant: GENENTECH, INC. ,  CONVELO THERAPEUTICS, INC.

Inventor： William VERNIER ,  Matthew VOLGRAF ,  Marie-Gabrielle BRAUN ,  Georgette Marie CASTANEDO ,  Paul Anthony GIBBONS ,  James Guy BREITENBUCHER ,  Drew ADAMS ,  Brad LANG

IPC: C07D495/10 ,  A61K31/407 ,  A61K31/4155 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/506

Abstract: The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of myelin-related disorders.

公开(公告)号：US20190263793A1

公开(公告)日：2019-08-29

申请号：US16140392

申请日：2018-09-24

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle BRAUN ,  Emily HANAN ,  Steven T. STABEN ,  Robert Andrew HEALD ,  Calum MACLEOD ,  Richard ELLIOTT

IPC: C07D413/14 ,  C07D267/08 ,  A61K31/553 ,  C07D498/04

Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

公开(公告)号：US20240391930A1

公开(公告)日：2024-11-28

申请号：US18670537

申请日：2024-05-21

Applicant: GENENTECH, INC. ,  CONVELO THERAPEUTICS, INC.

Inventor： Marie-Gabrielle BRAUN ,  Georgette CASTANEDO ,  William VERNIER ,  Matthew VOLGRAF ,  Michael SIU ,  James Guy BREITENBUCHER

IPC: C07D495/10 ,  A61K31/4155 ,  A61K31/4196 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506

Abstract: The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

公开(公告)号：US20210246129A1

公开(公告)日：2021-08-12

申请号：US17075583

申请日：2020-10-20

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle BRAUN ,  Emily HANAN ,  Steven T. STABEN ,  Robert Andrew HEALD ,  Calum MACLEOD ,  Richard ELLIOTT

IPC: C07D413/14 ,  C07D498/04 ,  A61K31/553 ,  C07D267/08

Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.